SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma.
Respir Res
; 21(1): 264, 2020 Oct 13.
Article
in En
| MEDLINE
| ID: mdl-33050928
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Asthma
/
Adrenal Cortex Hormones
/
Antibodies, Monoclonal, Humanized
Type of study:
Clinical_trials
Limits:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Respir Res
Year:
2020
Type:
Article
Affiliation country:
United States